Posted by Michael Wonder on 10 Apr 2025
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
10 April 2025 - Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously received at least one line of therapy containing a PD1 or PD-L1 inhibitor.
